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b-catenin, a major component of the cadherin adhesion system,
binds to both E-cadherin cytoplasmic and a-catenin amino-
terminal domains (Ozawa et al, 1989; Gumbiner, 1996). Recent
studies have revealed that b-catenin also acts as a down-stream
component of the Wingless/Wnt signalling pathway in Drosophila
(Peifer et al, 1992). Although the role of b-catenin in signal
transudation is not fully understood, the free cytoplasmic type has
been considered to be able to interact with DNA-binding proteins
of the T cell factor-lymphoid enhancer factor (Tcf-Lef) family
(Beherens et al, 1996; Molenaar et al, 1996). 
The adenomatous polyposis coli (APC) protein regulates free
b-catenin levels, together with glycogen synthetase kinase-3b
(GSK-3b) via phosphorylation of multiple serine/threonine
residues encoded by exon 3 of the b-catenin gene, through the
ubiquitin-proteasome pathway. Increase of free b-catenin may
result from either APC inactivation or b-catenin mutations, with
oncoprotein action through b-catenin-Tcf-regulated transcription
(Aberle et al, 1997; Morin et al, 1997; Orford et al, 1997). A
possible association between mutations of the b-catenin gene at
putative GSK3b phosphorylation sites and nuclear accumulation
has been reported in a variety of human malignancies, such as
colorectal carcinomas with a normal APC gene, melanomas, and
ovarian carcinomas (Rubinfeld et al, 1997; Palacios and Gamallo,
1998; Sparks et al, 1998). 
The endometrial carcinoma is a common malignancy of the
female reproductive tract. Although two distinctly different
pathways of endometrial tumour development from hyperplasia
(hyperplasia-carcinoma sequence) or postmenopausal endomet-
rium, have been proposed (Deligdisch and Cohen, 1985), the
underlying genetic mechanisms remain to be detailed. In this
study, to clarify the possible role of b-catenin abnormalities, we
investigated expression at the mRNA and protein levels, and muta-
tions in exon 3 at or near the sites of targets of GSK3 b phos-
phorylation in normal, hyperplastic and malignant endometrium. 
MATERIALS AND METHODS 
Cases 
A total of 199 cases of endometrial carcinoma (endometrioid
type), surgically resected at the Kitasato University Hospital from
1988 to 1999, were consecutively investigated for immunohisto-
chemistry, along with 141 normal samples (113 atrophic or prolif-
erative and 28 secretory stages) distant from carcinomas. 37 cases
of simple or complex hyperplasia without atypia and 32 of atypical
hyperplasia were also examined. All tissues were routinely fixed
in 10% formalin and processed for embedding in paraffin wax.
Histological diagnoses were performed according to the criteria
of the International Federation of Gynecology and Obstetrics
(FIGO). The carcinoma cases comprised 128 grade (G) 1, 39 G2,
and 32 G3 lesions. Areas of squamous differentiation (SqD) within
tumours, including squamous metaplasia (SqM) and morules,
were classified after Zaino et al (1991), the former being identified
in 28 cases and the latter in 27. Of carcinoma cases available for
investigation of clinicopathological factors, 143 were classified as
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myometrial invasion (less than half of myometrial depth) and 81
lower invasion. For nodal status in pelvic cavity and para-aortic
sites, 32 (16 of 139 stage I and 16 of 53 stages II–IV tumours)
featured metastasis and 160 were without apparent metastasis. 
Of 199 carcinoma cases, 73 tumours (43 G1, 18 G2, and 12 G3)
as well as 44 normal endometrial samples were snap-frozen in
liquid nitrogen and stored at 280˚C until use for mRNA expres-
sion, mutation, and Western blot analyses. 
Immunohistochemistry 
Immunohistochemistry was performed using a combination of
the microwave-oven heating and standard streptavidin-biotin-
peroxidase complex (LSAB kit, Dako, Copenhagen, Denmark)
methods. Briefly, slides were heated in 10 mM citrate buffer (pH
6.0) for three 5-min cycles using a microwave oven and then incu-
bated overnight at 4˚C with anti-b-catenin monoclonal antibody
(´1000 dilution, Transduction Lab, Lexington, NY). To confirm
the specificity of binding, normal mouse serum (´500 dilution)
was supplied instead of primary antibody as a negative control. 
Immunostaining patterns were divided into two types, cell
membrane and nuclear, with or without cytoplasmic, staining. For
the membrane staining type, the immunointensity was sub-
classified into 4 groups in comparison with an internal control as
follows: 0, negative; 1+, weak; 2+, moderate; and 3+, strong. The
immunointensity for normal endometrium adjacent to carcinoma
as the internal positive control was set as 3+. Positive immuno-
reactivity was concluded with either 2+ or 3+. Membrane labelling
index (M-LI) values were calculated after examining all positive
membrane signals from among at least 1000 cells in 5 randomly
selected fields in sections containing typical areas within tumours
for each case, using high-power (´40 objective and ´10 ocular)
magnification. Nuclear labelling index (N-LI) values were also
calculated in a similar manner, counting cells with nuclear
staining. On the basis of N-LI values, the lesions were subdivided
into three categories, in accordance with the criteria of previous
studies (Kondo et al, 1999; Nhieu et al, 1999) with minor modi-
fications, as follows: less than 1% N-LIs, more than 1% but less
than 10%, and more than 10%. Cases with N-LI values more than
1% were considered as positive in line with the results for relation
to gene mutations (Table 4). 
RT-PCR and Southern blot hybridization 
Total cellular RNA was extracted using Isogen (Nippon Gene Co.,
Tokyo, Japan) and cDNA was synthesized from 5 mg of total RNA
using RAV-2 reverse transcriptase (Takara, Shiga, Japan) in the
presence of random primers (Takara) and a ribonuclease inhibitor
(Takara) in a 20 ml reaction volume at 42˚C for 60 min. The tissue
samples used included at least 70% tumour elements as confirmed
by histopathological examination of adjacent sections to those
taken for mRNA analysis. 
For semi-quantitation of b-catenin gene expression, co- 
amplification with b-actin gene was carried out using 2 ml of
cDNA solution and Taq polymerase (Takara) in a 20 ml
volume. Specific primers for b-catenin (sense, 5¢-CCAGCGTGGA-
CAATGGCTAC-3¢ at exon 2 and antisense, 5¢-TGAGCTCGA-
GTCATTGCATAC-3¢ at exon 4) and b-actin (sense,
5¢-TGCTATCCAGGCTGTGCTAT-3¢ and antisense, 5¢-GATG-
GAGTTGAAGGTAGTTT-3¢) were applied. The PCR procedure
was performed with 30 cycles of denaturation at 94˚C for 0.5 min,
annealing at 55˚C for 0.5 min and extension at 72˚C for 0.5 min,
with a final extension time of 5 min. As a positive control, normal
squamous epithelium of uterine crevix was used since it has been
demonstrated to exhibit strong b-catenin expression (de Boer et al,
1999; Kimura et al, 1999). Water was supplied instead of template
DNA for each examination as a negative control. The quality of
the cDNAs was confirmed with GAPDH gene specific primers
(forward, 5¢-TGATGACATCAAGAAGGTGGTGAAG-3¢; reverse,
5¢- TCCTTGGAGGCCATGTAGGCCAT-3¢). 
A 2 ml aliquot of each PCR reaction mixture was electrophoresed
in a 2.5% agarose gel and transferred to a Hybond N nylon
membrane (Amersham, Tokyo Japan). Filters were hybridized
overnight with digoxigenin-labelled specific probes for both b-
catenin (5¢-ATATTGATGGACAGTATGCAA-3¢ at exon 4) and 
b-actin (5¢-ACTGACTACCTCATGAAGATCCTCACCGAG-3¢).
Hybridization signals were detected with a DIG Luminescent
Detection Kit (Boehringer Mannheim). The conditions used for
hybridization, washing, and detection were in line with the manu-
facturer’s recommendations. 
Analysis of hybridization signals was achieved with the
computer software NIH Image version 1.58. The relative amounts
were calculated by normalization to the hybridization signals for
b-actin in each case: the value for mRNA signals for b-catenin was
divided by that for the latter. 
DNA extraction and PCR 
DNA was extracted and purified from 32 cases of atypical hyper-
plasia through proteinase K/phenol-chloroform treatment. Six
serial 4 mm thick paraffin wax sections were cut from each case
and reviewed microscopically, and areas with at least 80% atypical
hyperplastic lesions were microdissected. 
A 148 bp fragment of exon 3 of the b-catenin gene was amplified
in hemi-nested PCR reactions. The first PCR conditions in a
volume of 10 ml with common forward (5¢-ATTTGATGGAGTTG-
GACATGG-3¢) and outer reverse (5¢- TGTTCTTGAGTGAAG-
GACTGA-3¢) primers were as follows: 30 cycles of 94˚C for
0.5 min, 55˚C for 1 min, and 72˚C for 1 min. Two ml aliquots of
reaction products were then used for a second PCR reaction in a
volume of 20 ml with the same reaction conditions, using inner
reverse (5¢-TCTTCCTCAGGATTGCCTT-3¢) primers. As a nega-
tive control, water was supplied instead of template DNA for each
examination. 
Sequencing analysis 
The remaining 18 ml aliquot of RT-PCR products for normal and
carcinoma samples and 20 ml of the amplicons for atypical hyper-
plasias were purified from agarose gels using a QIAEXII gel
extraction kit (Qiagen KK, Tokyo, Japan) and sequenced using
ABI PRISM Dye Terminator Cycle Sequencing Ready Reaction
Kit with AmpliTaq DNA Polymerase, FS (Perkin-Elmer, Foster
City, CA), according to the manufacturers’ protocols. The DNA
sequence was collected and analysed on an ABI Prism 310 auto-
mated DNA sequencer. The PCR primers were used for
sequencing the two strands of the amplified products. 
Western blot assay 
The remaining tissues of RNA extraction were homogenized in
0.01 M phosphate-buffered saline (PBS) solution and clarified by
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sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis
and then electroblotted (100 mÅ for one hour) onto Immobilon-P
(Millipore, Tokyo, Japan). After blocking, the filters were incub-
ated overnight at 4˚C with anti-b-catenin monoclonal antibody
(´1000 dilution, Transduction Lab) and anti-actin monoclonal
antibody (CP01, CALBIOCHEM, Cambridge, MA). As a pos-
itive control, normal uterine cervical squamous epithelium was
also used. Reactivity was visualized using the Western Blot
Chemiluminescence Reagent (NEN Life Science Products,
Boston, MA). 
Statistics 
Comparative data were analysed using the Mann-Whitney U-test,
the Pearson’s correlation coefficient and the chi-square test. The
cut-off for statistical significance was defined as P < 0.05. 
RESULTS 
Immunohistochemistry 
In normal endometrium, strong membrane b-catenin immunore-
activity was diffusely observed in glandular cells, showing similar
average M-LI values between atrophic/proliferative (97.1 ± 4.1%,
mean ±SD) and secretory (97.8 ± 3.1%) phases. The majority of
stromal and myometrial components were negative, while
endothelial cells in some capillaries showed moderate to strong
membrane immunostaining (Figure 1 a,b,g,h). Nuclear staining
was not found in any normal tissue elements (Table 1). 
Membrane b-catenin immunoreactivity in hyperplastic lesions
was similar to that in normal glandular components, while nuclear
with negative or weak cytoplasmic immunostaining (N-LI ^ 1%)
was noted in 4 (10.8%) of 37 simple or complex and in 10 (31.3%)
of 32 atypical hyperplasias (Figure 1 c,d,i,j), but the difference did
not reach significant when subdivision was into three categories on
the basis of the N-LI values (Table 1). 
A variety of b-catenin staining patterns were observed in
endometrial carcinomas, ranging from diffuse strong membrane
staining to a complete lack (Figure 1 e,f,k,l). Nuclear, with or
without cytoplasmic, immunostaining (N-LI ^ 1%) was apparent
in 55 (27.6%) of 199 carcinomas, being significantly related to
the grade of histological malignancy (Table 1). In two cases with
coexistence of carcinoma and atypical hyperplasia lesions,
membrane immunoreactivity for b-catenin appeared to be
decreased in the former as compared to the latter, while nuclear
immunoreactivity was negative in both lesions. 
Average LI values for b-catenin membrane staining were signi-
ficantly decreased in the sequence leading from normal or non-
atypical hyperplastic endometrium, through atypical hyperplasia,
b-catenin in endometrial tumours 211
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Figure 1 Semiserial sections of normal, hyperplastic, and malignant endometrium. a–f) H&E staining. g–l) b-catenin immunohistochemistry. In proliferative (a)
and secretory (b) phases of normal endometrium, strong b-catenin immunoreactivity is observed for cell membranes but not nuclei of glandular cells, while a
lack of any immunoreaction is evident for stromal components (g, h), with the exception of endothelial cells in capillaries (h), indicated by the arrow. Strong
membrane staining is also apparent in a complex hyperplasia (c, i), while the antibody against b-catenin also binds to nuclear sites in atypical hyperplasia (d, j).
Note the strong nuclear and cytoplasmic but relatively weak membranous immunoreactivity in a grade 1 carcinoma (e, k) and weak membranous binding
without nuclear accumulation in a grade 3 tumor (f,l). Higher magnification (´520) views of areas indicated by arrows are provided in the insets (j, k). Original
magnification, ´200.to grade 3 carcinoma (Figure 2A), while there were no differences
in N-LI values among non-atypical and atypical hyperplastic and
carcinoma lesions (Figure 2B). 
In both hyperplasias and carcinomas, the average M-LI values
in nuclear immunopositive groups (N-LIs ^ 1%) were signific-
antly lower than in their negative counterparts (Figure 3). 
The  b-catenin antibody also bound to areas of SqD within
tumours (Figure 4A), but average M-LI values, in particular in
morules, were significantly lower than in carcinomatous areas, in
contrast to significantly higher N-LIs (Figure 4B). 
No apparent correlation between either membrane or nuclear
immunopositivity and several clinicopathological parameters
investigated was observed for the carcinoma category, with the
exception of relation between M-LIs and degree of histological
malignancy (Table 2). 
mRNA expression and analysis of b-catenin gene
mutations 
By co-amplification assay with b-actin gene, RT-PCR products of
the b-catenin gene with the expected molecular weight (290 bp)
were detected in all normal and tumour samples investigated, no
small bands (less than 290 bp) being identified (Figure 5A).
No differences in the relative mRNA intensity were observed. In
addition, the mRNA expression levels were not related to any
immunohistochemical parameters or clinicopathological factors
investigated for endometrial carcinomas (data not shown). 
Sequence analysis for the RT-PCR amplicons of b-catenin exon
3 revealed heterozygous substitution mutations in 16 (22.9%) of
70 informative tumour cases, whereas no mutations were noted in
12 normal samples. Data for endometrial cases with b-catenin
mutations are summarized in Table 3. Mutations at potential phos-
phorylation target residues (serine/threonine at codons 33, 35, 37,
41 and 45) were detected in 14 (87.5%) of 16 cases, the remaining
2 cases being mutated at codon 34. The most common type of
mutation was a C:G to T:A transition, present in 9 (56.3%) cases,
with an A:T to C:G transition in 3, and a C:G to G:C transversion
in 4 (Figure 5B). Mutations at codon 33 were also detected in 3
(12.5%) of 24 informative atypical hyperplasia cases, with a C:G
to G:C transversion in 2 and a C:G to A:T transition in one case. 
As shown in Table 4, b-catenin mutations were significantly
correlated with grade 1 or 2 tumours, low M-LIs, high N-LIs, and
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Table 1 Nuclear b-catenin expression in normal, hyperplastic, and malignant endometrium 
b-Catenin nuclear staining (%) 
n N-LI<1% 1% % N-LI<10% 10% % N-LI P value 
Carcinoma 
Grade 1 128 91 (71.1) 25 (19.5) 12 (9.4) 
Grade 2 39 27 (69.2) 12 (30.8) 0 0.039 
Grade 3 32 26 (91.3) 2 (6.2) 4 (12.5) 
Hyperplasia 
Non-atypical 37 33 (89.2) 4 (10.8) 0
Atypical 32 22 (68.8) 7 (21.9) 3 (9.3)
Mutation (+) 3 0 3 (100) 0
(–) 21 15 (71.4) 3 (14.3) 3 (14.3) 
Normal 141 141 (100) 0 0 
N-LI, nuclear labelling index; n, number of cases; Mutation, exon 3 mutation of the b-catenin gene in
atypical hyperplasias. Statistical analysis was performed with the chi-square test. 
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Figure 2 Immunoreactivity score for cell membrane b-catenin staining. N, normal endometrium; H, non-atypical hyperplasia; AH, atypical hyperplasia; G,
grade. The data are mean ± SD values. Statistical analysis was performed using the Mann-Whitney U-test. 
0.058
0.006 negative lymph node metastasis. Positive relation to nuclear
immunopositivity was also evident, as well as that of atypical
hyperplastic lesions (Table 1), but there was no association with
the relative mRNA intensity levels. 
Western blot assay 
In cases available for Western blot analysis, bands of b-catenin
showed a molecular weight of 92 kDa with or without 
several lower fragments, probably due to protein degradation, but
truncated products were not observed (Figure 5C). Positive signals
were detected in 29 (96.7%) of 30 normal samples and in 58
(85.3%) of 68 carcinomas (Table 3), no association with relative
mRNA intensity, the presence of mutations, or immunohistochem-
ical results being evident. 
DISCUSSION 
In an endometrial cancer cell line, cell to cell aggregation and
expression of E-cadherin, a- and b-catenin mRNAs have been
reported to be significantly suppressed by estrogen with reversal
by progesterone, suggesting regulation of the cadherin-associated
cell adhesion system by sex steroid hormones (Fujimoto et al,
1996). Our results, however, did not show any differences in
membrane  b-catenin expression among atrophic, proliferative, and
secretory phases in normal endometrium. 
Nuclear b-catenin accumulation with or without mutations in
exon 3 of the gene in atypical hyperplasia appeared to be higher
than in simple or complex hyperplasias, the majority of the latter
regressing or remaining stable, while approximately 30% of atyp-
ical hyperplasia progress to low-grade carcinomas (Kerman,
1985). Yoshinaga et al (1998) also proposed that atypical hyper-
plasias are at high risk for cancer development, whereas simple or
complex hyperplasias are not, on the basis of microsatellite
analyses. Considering the two proposed pathways of endometrial
tumorigenesis (Deligdisch and Cohen, 1985), we therefore
conclude that alteration in b-catenin expression may play an
important role in a relatively early event in the endometrial hyper-
plasia-carcinoma sequence. Similar observations have been
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Figure 3 Relation between b-catenin membrane and nuclear
immunostaining. N, negative for nuclear immunopositivity; P, positive. The
data are mean ± SD values. Statistical analysis was performed using the
Mann-Whitney U-test 
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Figure 4 (A) Immunoreactivity for b-catenin in areas of squamous differentiation within an endometrial carcinoma. (A–a) Note the strong nuclear
immunopositivity with a weak membrane immunoreaction in a morule (lower half). (A–b) Relatively weak membrane staining in a squamous metaplastic area
(lower half) as compared to the glandular portion. (B) Immunoreactivity scores for b-catenin membrane staining among carcinoma (Ca), morule (Mu), and
squamous metaplastic (SqM) lesions. The data are mean ± SD values. Statistical analysis was performed using the Mann-Whitney U-test demonstrated for colorectal and ovarian endometrioid tumorigen-
esis (Palacios and Gamallo, 1998; Samowitz et al, 1999). 
In this study, we identified mutations in exon 3 of the b-catenin
gene in 16 (22.9%) of 70 endometrial carcinomas, in line with
previous studies (Fukuchi et al, 1998; Kobayashi et al, 1999;
Mirabelli-Primdahl et al, 1999). Although our mutation analysis
was limited, it has been reported that mutations outside exon 3 of
the  b-catenin gene was infrequent, despite the entire coding
sequence was analysed (Ilyas et al, 1997). In our series, the muta-
tions in most cases (14 of 16) involved the loss of serines or 
threonines from GSK-3 b phosphorylation sites (codons 33, 35,
37, 41 and 45), as reported earlier (Fukuchi et al, 1998; Palacios
and Gamallo, 1998; Garcia-Rostan et al, 1999; Mirabelli-Primdahl
et al, 1999). Two cases showed a glycine to glutamic acid substitu-
tion at codon 34 which did not involve phosphorylation regions,
but this abnormality is considered to interfere with b-catenin
degradation by altering recognition sequences or tertiary protein
structure (Sparks et al, 1998). 
Although APC mutations may lead to stabilization or accumula-
tion of b-catenin protein (Aberle et al, 1997; Orford et al, 1997),
they are rare events in endometrial carcinomas (Jones et al, 1994;
Berchuck and Boyd, 1995). In this study, b-catenin mutations in
exon 3 was significantly related to low membrane and high
nuclear immunoreactivity but not the relative mRNA intensity.
Considering our findings for significant decrease of the membrane
b-catenin expression together with the nuclear accumulation,
gene mutations may be closely linked with an altered subcellular
distribution rather than overexpression of mutated products in
endometrial carcinomas. The finding of a possible reciprocal rela-
tion between loss of membrane expression and nuclear localiza-
tion of b-catenin in colorectal carcinomas is interesting in this
context (Hao et al, 1997). Our results that 6 carcinoma and 6 atyp-
ical hyperplasia cases without mutations also exhibited a distinct
nuclear immunostaining may indicate the presence of other molecu-
lar pathways for b-catenin stabilization; for example, it has been
reported that the wnt-1 oncogene promotes the accumulation of b-
and g-catenin (Hinck et al, 1994). 
As another possible mechanism of b-catenin stabilization, somatic
interstitial deletions of b-catenin exon 3, along with small transcripts
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Table 2 Relation between either membrane or nuclear b-catenin immunoreactivity and
clinicopathological factors in endometrial carcinomas 
Membrane LI Nuclear LI 
n m ± SD P value m ± SD P value 
Histology 
Grade 1 128 64.9 ± 22.4 2.8 ± 6.2 
Grade 2 39 44.6 ± 20.9 1.6 ± 2.7 
Grade 3 32 31.7 ± 20.8 a 5.1 ± 18.2 NS 
FIGO stage 
I 143 57.6 ± 25.6 2.8 ± 9.5
II/III/IV 56 50.6 ± 24.5 0.08 3.3 ± 7.0  0.48 
Myometrial invasion 
Upper 118 56.3 ± 26.1 3.7 ± 11.0
Lower 81 54.7 ± 24.5 0.62 1.8 ± 4.0 0.51 
LN metastasis 
Positive 32 49.3 ± 25.0 1.3 ± 3.1
Negative 160 57.3 ± 24.9 0.09 3.0 ± 9.4 0.37 
Ll, labelling index; m, mean; LN, lymph node; a, Grade 1 vs. Grade 2, P < 0.0001, Grade 1 vs.
Grade 3, P < 0.0001, Grade 2 vs. Grade 3, P = 0.025; NS, not significant. Statistical analysis was
performed with the Mann-Whitney U-test. 
b) b-Catenin mutation (–)
a) b-Catenin mutation (+)
C11
C3 C4 C24 C26 C44 N1 N2 N3 N4 N5 p n
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Figure 5 (A)R T -PCR and Southern blot hybridization analysis for b-catenin
mRNA in mutation positive (a) and negative (b) groups, with co-amplification
of b-actin gene. Amplicons for GAPDH gene are also demonstrated as
internal controls for each case. Case numbers for tumoirs with mutations
correspond to those in Table 3. C, carcinoma cases; N, normal endometrial
tissues; p, positive control (normal uterine cervical tissue); n, negative control
(water). (B) Sequencing data for atypical hyperplasia (A20) and endometrial
carcinomas (C11, C16, C36, and C74). (C) Western blot analysis of
carcinoma (C) and normal (N) samples. After detection of b-catenin proteins,
the filter was stripped to be incubated with an antibody against actin.
p, positive control (normal uterine cervical tissue)b-catenin in endometrial tumours 215
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 and the truncated proteins lacking 76 amino acids, have been
reported in colorectal carcinomas with wild type APC (Iwao et al,
1998). Such aberrant transcripts and proteins in our series,
however, could not be demonstrated in any of tumours investigated,
although we did not perform genomic DNA analyses. 
With regard to the clinical implications of b-catenin abnormal-
ities, colorectal adenomas with mutations have been demonstrated
to be less likely to progress to larger adenomas and invasive carcin-
omas (Samowitz et al, 1999). In endometrial carcinomas, the alter-
ations have been considered to be related to an early clinical stage
with well differentiated histology or early onset of endometrial
carcinomas (Fukuchi et al, 1998; Kobayashi et al, 1999). In addi-
tion to histological malignancy, we also found a significant corre-
lation with no lymph node metastasis. This observation supports
our conclusion of an association between b-catenin alterations
and the endometrial hyperplasia-carcinoma sequence, since carci-
nomas developing with background of hyperplasia exhibit slow
growth, spontaneous regression, and limited metastatic potential
as compared to tumours arising from non-hyperplastic
endometrium (Kurman et al, 1985). A lack of association between
N-LI values and nodal metastasis may be due to the presence of
tumours showing nuclear b-catenin accumulation without muta-
tions of the gene. 
We previously demonstrated aberrant DCC (deleted in colon
cancer) and bcl-2 expression in morules as compared with SqM
and primary tumour lesions (Saegusa and Okayasu, 1997; Saegusa
et al, 1999). In this study, a high frequency of b-catenin nuclear
localization was evident in morules but not SqM areas within
tumours, indicating changes in expression of various molecules
during development of morule foci. 
A lack of correlations among mRNA, Western blot, and immuno-
histochemical findings was observed in this study. Possible reasons
for this anomaly include the following: 1. contamination with
endothelial cells expressing b-catenin; 2. degradation of protein
products during sample preparation and processing due to protease
activity; 3. differences in the protein fractions used in Western blot
assay, since membrane b-catenin is mainly found in insoluble
(membrane-bound) rather than soluble (cytoplasmic) fractions; 4.
differences in sensitivity among the three assays. Discrepant results
between levels of mRNA and protein have also been demonstrated
for CD44 and DCC genes (Woodman et al, 1996; Horstmann et al,
1997). We therefore concluded that the immunohistochemical
analysis is more accurate for assessment of actual levels of b-catenin
protein, although PCR-based assays may be more sensitive. 
In conclusion, the present study demonstrated a possible associ-
ation between b-catenin alteration and endometrial tumorigenesis
involving atypical hyperplastic lesions. 
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